Your only epithelioid mesothelioma news source!
Click on each item to read full story.

 
Concordia Healthcare Corp. announces first patients enrolled in Phase 2 clinical trial using Photodynamic Therapy with ...
read story
Concordia Healthcare Corp. announces first patients enrolled in Phase 2 clinical trial using Photodynamic Therapy with PHOTOFRIN(R) for patients with mesothelioma
 
CD157 important in malignant pleural mesothelioma
read story
CD157 plays a pivotal role in the progression of malignant pleural mesothelioma and may be useful in the stratification of patients into different prognostic groups, Italian research suggests.
 
Test Results Look Promising for New Mesothelioma Blood Test, According to Surviving Mesothelioma
read story
Japanese researchers report good results with a new, more sensitive test for a key mesothelioma biomarker. (PRWeb July 28, 2014) Read the full story at http://www.prweb.com/releases/2014/07/prweb12046860.htm
 
Concordia subsidiary enrolls patients in Phase 2 trial to evaluate PDT with PHOTOFRIN in mesothelioma
read story
Concordia Healthcare Corp., a diverse healthcare company focused on legacy pharmaceutical products, orphan drugs, and medical devices for the diabetic population, announced today that its subsidiary Pinnacle Biologics, Inc., a biopharmaceutical research and development company specializing in rare diseases, enrolled the first patients in a randomized Phase 2 trial to evaluate Photodynamic ...
 
Sector Update: Healthcare; Cardiome Posts Wider Q2 Loss, Concordia Healthcare Enrolls First Patients in Phase 2 Trial ...
read story
Sector Update: Healthcare; Cardiome Posts Wider Q2 Loss, Concordia Healthcare Enrolls First Patients in Phase 2 Trial of Photodynamic Therapy with PHOTOFRIN
 
Concordia Healthcare Corp. Announces Financial and Operational Results for its Second Quarter, Ended June 30, 2014
read story
Concordia Healthcare Corp. Announces Financial and Operational Results for its Second Quarter, Ended June 30, 2014